37 filings · most recent first
BBIO 8-K Filings
Bridgebio Announces Fda Acceptance Of Nda For Encaleret For Adh1
Bridgebio Announces 500 Million Share Repurchase Program
Bridgebio Reports Q4 And Full Year 2025 Financial Results
Bridgebio Reports Q3 2025 Financial Results And Business Updates
Bridgebio Raises 1 Billion In Preferred Equity To Fund Growth
Dr Randal W Scott Resigns From Bridgebio Pharma Board
Bridgebio Secures Fda Priority Review For Bbp418 In Lgmd2Ir9
Bridgebio Submits Nda To Fda For Encaleret For Adh1 Treatment
Bridgebio Pharma Enters New Equity Distribution Agreement
Bridgebio Submits Nda For Bbp418 To Treat Lgmd2Ir9
Bridgebio Announces Positive Phase 3 Results For Oral Infigratinib In
Bridgebio Issues Convertible Senior Notes Due 2033
Bridgebio Announces Preliminary Financials And Business Updates For 2025
Bridgebio Announces Positive Phase 3 Results For Encaleret In Adh1
Bridgebio Announces Positive Phase 3 Results For Bbp418 In Lgmd2Ir9 Fortify
Bridgebio Pharma Announces Royalty Interest Sale For 300M
Bridgebio Pharma Inc Shareholders Approve Officer Exculpation Amendment
Bridgebio Appoints New Cfo And Announces Succession Plan
Bridgebio Launches Convertible Senior Notes Offering And Repays Existing Debt
Bridgebio Announces Strong Demand For Attruby And Progress On Clinical Trials
Fda Approves Bridgebio8217S Attruby For Attrcm Treatment
Bridgebio Pharma Reports Topline Results From Phase 12 Trial Of Investigational
Bridgebio Pharma Inc Forms Joint Venture With Investors To Research And
Bridgebio Appoints Thomas Trimarchi As President And Coo
Bridgebio Pharma Inc Annual Meeting Results And Plan Amendment Approval
Bridgebio Announces Positive Phase 2 Results For Infigratinib In Achondroplasia
Bridgebio Pharma Announces 250 Million Public Offering
Bridgebio Pharma Inks Exclusive License Agreement With Bayer For Acoramidis In
Bridgebio Pharma Enters Into 500M Funding Agreement And Refinances Existing Loan
Bridgebio Pharma Presents Business Update At Jp Morgan Healthcare Conference
Bridgebio Pharma Reports Second Quarter 2025 Financial Results
Bridgebio Reports Q1 2025 Financial Results And Business Updates
Bridgebio Reports Strong Financial Results And Commercial Progress For Attruby
Bridgebio Pharma Reports Third Quarter 2024 Financial Results And Business
Bridgebio Reports Q2 2024 Financial Results And Business Updates
Bridgebio Reports Q1 2024 Financial Results And Business Updates
Bridgebio Pharma Reports Q4 And Fullyear 2023 Financial Results And Business